Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient

• Autores principales: Reynolds Jamie PharmD (Autor), Gramlich Nicole PharmD, BCPP (Autor)
• Formato: Libro
• Publicado: American Association of Psychiatric Pharmacists, 2023-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.
• Notes: 2168-9709; 10.9740/mhc.2023.06.159
• Keywords: terbinafine; drug interactions; risperidone; cyp2d6 inhibitor; Neurosciences. Biological psychiatry. Neuropsychiatry; RC321-571; Pharmacy and materia medica; RS1-441
• Source: Mental Health Clinician, Vol 13, Iss 3, Pp 159-162 (2023)

Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.